{"nctId":"NCT04546724","briefTitle":"Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults","startDateStruct":{"date":"2020-09-17","type":"ACTUAL"},"conditions":["Chikungunya Virus Infection"],"count":4128,"armGroups":[{"label":"VLA1553","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: VLA1553"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"VLA1553","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 years of age or above on the Day of screening\n2. able to provide informed consent\n3. generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests\n4. for women of childbearing potential:\n\n   1. practiced an adequate method of contraception during 30 days before screening\n   2. negative serum or urine pregnancy test at screening\n   3. agreed to employ adequate birth control measures for the first three months post-vaccination.\n\nMain Exclusion Criteria:\n\n1. CHIKV infection in the past, including suspected CHIKV infection; was taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or had participated in a clinical study involving an investigational CHIKV vaccine\n2. acute or recent infection\n3. Subject tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);\n4. live virus vaccine within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or planned to receive a vaccine within 28 days or 14 days after vaccination, respectively\n5. abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator which pose a risk for participation in the study\n6. medical history of or currently had acute or progressive, unstable or uncontrolled clinical conditions that posed a risk for participation in the study\n7. history of immune-mediated or clinically relevant arthritis / arthralgia\n8. history of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there had been surgical excision or treatment more than 5 years ago that was considered to have achieved a cure, the subject could be enrolled.\n9. known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination.\n10. history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications)\n11. with clinical conditions representing a contraindication to intramuscular vaccination and blood draws\n12. pregnant or lactating at the time of enrollment\n13. Donation of blood, blood fractions or plasma within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or planned to donate blood or used blood products until Day 180 of the study\n14. rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating\n15. known or suspected problem with alcohol or drug abuse as determined by the Investigator\n16. any condition that, in the opinion of the Investigator, could compromise the subjects well-being, interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;\n17. committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities)\n18. Participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study\n19. member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a Seroprotective CHIKV Antibody Level for Baseline Negative Subjects 28 Days Post-vaccination","description":"Seroprotection rate, based on a surrogate of protection agreed with FDA\n\nAssay used for analysis was based on µPRNT (Micro Plaque Reduction Neutralization Test). Participants at pre-selected sites were included, if they had available Day 1 and Day 29 samples and without major protocol deviations that could impact the immune response.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"CHIKV-specific Neutralizing Antibody Titers","description":"CHIKV-specific Neutralizing Antibody Titers on Day 8, and Day 29 Postvaccination as Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) Assay","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":null},{"groupId":"OG001","value":"10.2","spread":null},{"groupId":"OG002","value":"13.4","spread":null},{"groupId":"OG003","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3273.7","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"3688.8","spread":null},{"groupId":"OG003","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1068.7","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"1140.9","spread":null},{"groupId":"OG003","value":"10.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"755.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"742.8","spread":null},{"groupId":"OG003","value":"10.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroprotective CHIKV Antibody Level","description":"Seroprotection rate, based on a surrogate of protection agreed with FDA Seroprotective CHIKV Antibody Level Defined as μPRNT (Micro Plaque Reduction Neutralization Test) for Baseline Negative Subjects","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroconversion","description":"Seroconversion was defined as CHIKV-specific neutralizing antibody titer of ≥ 20 based on µPRNT (Micro Plaque Reduction Neutralization Test) for baseline negative subjects","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fold \"Change\" of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline","description":"Fold Change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"460.27","spread":"384.052"},{"groupId":"OG001","value":"1.02","spread":"0.140"},{"groupId":"OG002","value":"507.70","spread":"412.467"},{"groupId":"OG003","value":"1.00","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108.81","spread":"97.238"},{"groupId":"OG001","value":"1.00","spread":"0.000"},{"groupId":"OG002","value":"102.09","spread":"79.433"},{"groupId":"OG003","value":"1.00","spread":"0.000"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reaching an X-fold Change in CHICKV-specific Neutralizing Antibody Titer Compared to Baseline","description":"Number of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold change of CHIKV-specific Neutralizing Antibody Titers Determined by μPRNT ( (Micro Plaque Reduction Neutralization Test) as compared to baseline","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"57","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"181","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"56","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"35","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Unsolicited AEs","description":"Number of Participants with Unsolicited Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"687","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]}]},{"type":"SECONDARY","title":"Solicited Injection Site AEs","description":"Number of Participants with solicited injection site reactions","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"463","spread":null},{"groupId":"OG001","value":"115","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"328","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Solicited Systemic AEs","description":"Number of Participants with solicited systemic reactions","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1547","spread":null},{"groupId":"OG001","value":"278","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"969","spread":null},{"groupId":"OG001","value":"151","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"879","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"735","spread":null},{"groupId":"OG001","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"520","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"345","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Number of Participants with any Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1287","spread":null},{"groupId":"OG001","value":"336","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"532","spread":null},{"groupId":"OG001","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Related Adverse Events","description":"Number of Participants with any related Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1575","spread":null},{"groupId":"OG001","value":"322","spread":null}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Event","description":"Number of Participants with any Serious Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Related Serious Adverse Event","description":"Number of Participants with any Related Serious Adverse Events","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adverse Event of Special Interest","description":"Number of Participants with any Adverse Event of Special Interest\n\nAESI Definition:\n\nThe following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration:\n\n1. Fever (≥38.0°C \\[100.4°F\\] measured orally) and\n2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \\[foot plant\\] and edema of the face and extremities), polyadenopathies; and\n3. Onset of symptoms 2 to 21 days after vaccination and\n4. Duration of event ≥3 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Related Adverse Event of Special Interest","description":"Number of Participants with any Related Adverse Event of Special Interest\n\nAESI Definition:\n\nThe following cluster of symptoms suggestive of CHIKV infection with or without remissions or exacerbations received particular consideration:\n\n1. Fever (≥38.0°C \\[100.4°F\\] measured orally) and\n2. Acute (poly)arthralgia/arthritis most frequently in the extremities (wrists, ankles, and phalanges, often symmetric), back pain and/or neurological symptoms (e.g. confusion, optic neuritis, meningoencephalitis, or polyneuropathy) and/or cardiac symptoms (e.g. myocarditis) or One or more of the following signs and symptoms: macular to maculopapular rash (sometimes with cutaneous pruritus \\[foot plant\\] and edema of the face and extremities), polyadenopathies; and\n3. Onset of symptoms 2 to 21 days after vaccination and\n4. Duration of event ≥3 days.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":46,"n":3082},"commonTop":["Headache","Fatigue","Myalgia","Arthralgia","Injection site pain"]}}}